Suppr超能文献

甲状腺疾病患者的血清骨钙素水平。

The serum osteocalcin levels in patients with thyroid diseases.

作者信息

Simionescu L, Dumitriu L, Dimitriu V, Zamfir-Grigorescu D, Câmpean G, Dumitriu E, Balmeş E, Simescu M, Gudovan E, Ursu H

机构信息

C. I. Parhon, Institute of Endocrinology, Bucharest, Romania.

出版信息

Endocrinologie. 1988 Jan-Mar;26(1):27-33.

PMID:3260397
Abstract

The mechanism of bone, calcium, phosphorus and proteins abnormalities observed in hyperthyroidism is rather complex and as yet not wholly understood. Increased serum osteocalcin was recently reported in hyperthyroid patients and its decrease after 4-8 months of treatment. Osteocalcin was measured by RIA in the sera of 211 women and 18 men with thyroid diseases. The patients were divided into 3 groups according to diagnosis: I. polynodular goitre and subacute thyroiditis (59 women, 5 men); II. Graves' disease (70 women, 3 men) and III. thyroid cancer, after treatment by surgery and 131I (82 women, 10 men). The osteocalcin levels in the sera of these patients were: 2.97 +/- 2.63 ng/ml (mean +/- SD) for the women and 3.56 +/- 2.10 ng/ml for the men in the 1st group; 16.31 +/- 11.34 ng/ml for the women and 12.75 +/- 6.09 ng/ml for the man in the IInd group and, 1.01 +/- 0.60 ng/ml for the women and 0.78 +/- 0.46 ng/ml for the men in the IIIrd group. No differences were found between the osteocalcin concentrations in the hyperthyroid female patients treated with antithyroid drugs (no = 58) and the non-treated hyperthyroid women (no = 12): 16.22 +/- 11.40 ng/ml vs 16.74 +/- +/- 11.53 ng/ml. These data suggest that bone resorption stimulated by endogenous thyroid-hormones is a rather resistant processus, persisting even after 6-8 mos of associated anti-thyroid therapy. Further are analyzed the possible causes of the subnormal osteocalcin levels observed in patients with thyroid cancer treated by surgery and radioisotope, whose suppression therapy was discontinued 2-3 weeks before blood sampling.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

甲状腺功能亢进症中所观察到的骨骼、钙、磷及蛋白质异常的机制相当复杂,至今尚未完全明了。最近有报道称甲状腺功能亢进症患者血清骨钙素升高,而治疗4 - 8个月后其水平下降。采用放射免疫分析法(RIA)测定了211名女性和18名男性甲状腺疾病患者血清中的骨钙素。根据诊断将患者分为3组:I. 多结节性甲状腺肿和亚急性甲状腺炎(59名女性,5名男性);II. 格雷夫斯病(70名女性,3名男性);III. 甲状腺癌,经手术和131I治疗后(82名女性,10名男性)。这些患者血清中的骨钙素水平分别为:第一组女性为2.97±2.63 ng/ml(均值±标准差),男性为3.56±2.10 ng/ml;第二组女性为16.31±11.34 ng/ml,男性为12.75±6.09 ng/ml;第三组女性为1.01±0.60 ng/ml,男性为0.78±0.46 ng/ml。接受抗甲状腺药物治疗的甲状腺功能亢进症女性患者(n = 58)与未治疗的甲状腺功能亢进症女性患者(n = 12)的骨钙素浓度无差异:分别为16.22±11.40 ng/ml和16.74±11.53 ng/ml。这些数据表明内源性甲状腺激素刺激的骨吸收是一个相当持久的过程,即使在联合抗甲状腺治疗6 - 8个月后仍持续存在。进一步分析了经手术和放射性同位素治疗的甲状腺癌患者血清骨钙素水平低于正常的可能原因,这些患者在采血前2 - 3周停用了抑制治疗。(摘要截选至250词)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验